Article Sidebar

PDF (Tiếng Việt)
Published: 2023-12-15
Abstract Views: 49
Views PDF (Tiếng Việt): 113
DOI: https://doi.org/10.52852/tcncyh.v171i10.2071
Issue
Vol. 171 No. 10 (2023)
Section
Các bài báo
How to Cite
Tùng, N. Q., & Ngọc, Đỗ H. . (2023). 37. Red blood cell recovery in allogeneic hematopoietic stem cell transplantation at the Central Institute of Hematology - Blood Transfusion from 2019 to 2022. Journal of Medical Research, 171(10), 321-330. https://doi.org/10.52852/tcncyh.v171i10.2071

37. Red blood cell recovery in allogeneic hematopoietic stem cell transplantation at the Central Institute of Hematology - Blood Transfusion from 2019 to 2022

Nguyen Quang Tung, Do Hong Ngoc

Main Article Content

Abstract

Providing data on red blood cell transplantation time would assists clinicians to prepare large volumes and to be able to make transfusion decisions appropriate to each stage of the transplant. The time and rate of red blood cell recovery in several groups of allogeneic hematopoietic stem cell transplant patients was analyzed in a retrospective case series of 37 patients receiving allogeneic stem cell transplant. Results showed that the mean reticulocyte engraftment of the minor ABO-incompatible group was 12.5 ± 2.2 days. The time for complete transformation into the donor derived - ABO type antigen was 15.3 ± 7.1 weeks. The mean time of RBC transfusion independence was 25 ± 18.2 days in patients receiving major ABO-incompatible transplantation; in the minor ABO-incompatible group it was 16.6 ± 10.2 days. The reticulocyte engraftment time of the major ABO-incompatible group was delayed in the minor ABO-incompatible group. The time for complete transformation into the donor derived - type ABO antigen was not different between the major group and the minor group. The major ABO-incompatible group tended to become RBC transfusion independence later than the minor ABO-incompatible group.

Article Details

Keywords

ABO-Mismatched, red blood cell engraftment, recovery reticulocyte, donor-derived ABO type antigen, allogeneic hematopoietic stem cell transplantation

References

1. Locatelli F, De Stefano P. Innovative approaches to hematopoietic stem cell transplantation for patients with thalassemia. Haematologica. 2005;90(12):1592-1594.
2. Armand P, Antin JH. Allogeneic Stem Cell Transplantation for Aplastic Anemia. Biology of Blood and Marrow Transplantation. 2007;13(5):505-516. doi:10.1016/j.bbmt.2007. 02.005
3. Worel N. ABO-Mismatched Allogeneic Hematopoietic Stem Cell Transplantation. Transfus Med Hemother. 2016;43(1):3-12. doi:10.1159/000441507
4. Schmaltz C, van den Brink MRM. Graft versus Leukemia and Graft versus Tumor Activity. In: Bertino JR, ed. Encyclopedia of Cancer (Second Edition). New York: Academic Press; 2002:325-338. doi:10.1016/B0-12-227555-1/00094-0
5. Pang A, Huo Y, Shen B, et al. Optimizing autologous hematopoietic stem cell transplantation for acute leukemia. Stem Cells Transl Med. 2021;10(Suppl 2):S75-S84. doi:10.1002/sctm.21-0176
6. Noronha JFA, De Souza CA, Vigorito AC, et al. Immature reticulocytes as an early predictor of engraftment in autologous and allogeneic bone marrow transplantation: Reticulocytes and bone marrow transplantation. Clinical & Laboratory Haematology. 2003;25(1):47-54. doi:10.1046/j.1365-2257.2003.00486.x
7. Worel N, Greinix H t, Schneider B, et al. Regeneration of erythropoiesis after related- and unrelated-donor BMT or peripheral blood HPC transplantation: a major ABO mismatch means problems. Transfusion. 2000;40(5):543-550. doi:10.1046/j.1537-2995.2000.40050543.x
8. Yildirim I, Ozer Y, Yüksel MK, et al. Erythrocyte antigen and reticulocyte engraftment after allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant. 2004;34(4):351-355. doi:10.1038/sj.bmt.1704576
9. Canals C, Muñiz-Díaz E, Martínez C, et al. Impact of ABO incompatibility on allogeneic peripheral blood progenitor cell transplantation after reduced intensity conditioning. Transfusion. 2004;44(11):1603-1611. doi:10.1111/j.1537-2995.2004.04106.x
10. Tomonari A, Takahashi S, Ooi J, et al. Impact of ABO incompatibility on engraftment and transfusion requirement after unrelated cord blood transplantation: a single institute experience in Japan. Bone Marrow Transplant. 2007;40(6):523-528. doi:10.1038/sj.bmt.1705765
11. Valentini CG, Metafuni E, Gallo L, et al. ABO Mismatch in Allogeneic Hematopoietic Stem Cell Transplant: Effect on Short- and Long-term Outcomes. Transplant Direct. 2021;7(8):e724. doi:10.1097/TXD.0000000000001179
12. Yuan S, Yang D, Nakamura R, et al. Red blood cell and platelet transfusion support in the first 30 and 100 days after allogeneic hematopoietic cell transplant. Transfusion. 2020;60(10):2225-2242. doi:10.1111/trf.15961
13. Lee JH, Lee JH, Choi SJ, et al. Changes of isoagglutinin titres after ABO-incompatible allogeneic stem cell transplantation. British Journal of Haematology. 2003;120(4):702-710. doi:10.1046/j.1365-2141.2003.04128.x
14. Blin N, Traineau R, Houssin S, et al. Impact of donor-recipient major ABO mismatch on allogeneic transplantation outcome according to stem cell source. Biol Blood Marrow Transplant. 2010;16(9):1315-1323. doi:10.1016/j.bbmt.2010.03.021
15. Greer JP, Arber DA, Glader BE, et al. Wintrobe’s Clinical Hematology: Fourteenth Edition. 14th ed. Wolters Kluwer Health Pharma Solutions (Europe) Ltd; 2018. http://www.scopus.com/inward/record.url?scp=85063312829&partnerID=8YFLogxK. Accessed October 15, 2023.